ClinicalTrials.gg
RecruitingNCT05549544LBBAP-AFHFUpdated Jan 10, 2024

Clinical Efficacy of Left Bundle Branch Area Pacing for Patients With Permanent Atrial Fibrillation and Heart Failure

An interventional study of Left bundle branch area pacing and Biventricular pacing in Left Bundle Branch Area Pacing, Biventricular Pacing and Heart Failure, sponsored by Fu Wai Hospital, Beijing, China. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Fu Wai Hospital, Beijing, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
180th of 247
60 · median 130
Started
2022
with 28 others
No phase
115 of 377
51 open now
Primary completion
2024-12
later than 17 of 181 live
Registered
178th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 180th largest by planned enrollment of the 247 interventional ones that give a count, is one of 29 that started in 2022, is one of 115 with no phase, reaches primary completion later than 17 of the 181 other live ones, and was the 178th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized controlled study. This study aims to compare the clinical efficacy of LBBAP with traditional biventricular pacing in patients with permanent atrial fibrillation and heart Failure

Read the detailed description

LBBAP-AFHF is a prospective, multicenter, randomized controlled trial that is designed to determine whether left bundle branch area pacing (LBBAP) may show superiority of improved LV function as compared with traditional biventricular pacing (BiVP) in patients with permanent atrial fibrillation and heart failure (LVEF\<50%) who receive atrioventricular nodal ablation due to fast ventricular rate or require high percentage of ventricular pacing due to slow ventricular rate. The primary endpoint of this trial is the change in the LVEF at 6 months after device implantation from baseline. A CRT-P/D device would be implanted and LBBAP lead would be connected to the RA port and LV lead to the LV port. Patients who receive successful LBBAP and BiVP simultaneously during the procedure would be 1:1 randomized to LBBAP or BiVP group after the procedure by device programming. Patients will be followed at 3 and 6 months post-discharge for LVEF and other echographic parameters (including LVESV, response rate), and rehospitalization for heart failure or all-cause death.

03

Conditions studied

  • Left Bundle Branch Area Pacing
  • Biventricular Pacing
  • Heart Failure
  • Permanent Atrial Fibrillation

Browse trials for

Keywords

  • Left Bundle Branch Area Pacing
  • Permanent Atrial Fibrillation
  • Heart Failure
  • Biventricular Pacing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged more than 18 years old
  • Patients diagnosed with heart failure (\<50%) and have received optimal medical therapy for at least 3 months
  • Patients with permanent atrial fibrillation (QRS duration \<130ms) which need ventricular pacing, including:

    1. LVEF\<50%, II-IV, drug- atrial fibrillation with the fast ventricular rate, planned atrioventricular nodal ablation due to 1). anticipated low success rate of atrial fibrillation catheter ablation or 2). patients refused to receive catheter ablation or 3). refused to receive another catheter ablation after a previous history of failed procedures
    2. LVEF\<50%, NYHA II-IV, atrial fibrillation with slow ventricular rate, anticipated ventricular pacing burden ≥ 40%
  • Written was provided

Exclusion criteria

Exclusion Criteria:

  • expected survival time is less than 12 months
  • Prior history of mechanical tricuspid valve replacement and/or congenital heart disease (including dextrocardia, transposition of the great arteries, single left persistent left superior vena cava, etc.)
  • Plan for PCI or CABG due to unstable angina or myocardial infarction in 3 months
  • Surgery is required within 1 year due to severe structural heart disease
  • Pregnancy, planned pregnancy or heart transplant
  • Prior history of HCM and/or ventricular septal defect repair, who are unlikely to achieve successful LBBAP procedure.
  • Failure of lead placement due to abnormal anatomy of the coronary sinus or enlarged right atrium, which makes it unable to switch from one pacing modality to another
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    LBBAP group

    Device: Left bundle branch area pacing(LBBAP) LBBAP is a novel physiological pacing form for ventricular pacing. In patients who received LBBAP, the pacing lead will be placed at the left bundle branch area to achieve a narrow-paced QRS duration.

    Device: Left bundle branch area pacing

  • Active comparator
    BiVP group

    Device: Biventricular pacing (BiVP) Biventricular pacing is the traditional pacing modality for patients with heart failure. For BiVP, one pacing lead was placed in the coronary sinus, named LV lead, and another lead was placed in the right ventricule.

    Device: Biventricular pacing

Interventions

  • DeviceLeft bundle branch area pacing

    Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.

  • DeviceBiventricular pacing

    Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure

06

What researchers measure

Primary outcomes

  1. ΔLVEF between baseline and six months post-discharge

    ΔLVEF:change in LVEF between baseline and six months after procedure

    Time frame: Six months after device implantation

Secondary outcomes

  1. The immediate success rate of the LBBAP procedure

    Successful LBBAP procedure is identified according to ECG and intracardiac ECG electrogram (IEGM) during the procedure. All LBBAP procedures will be categorized as selective left bundle branch pacing (S-LBBP), non-selective left bundle branch pacing(NS-LBBP), or left ventricular septal pacing (LVSP).

    Time frame: 1 weeks

  2. The rate of procedure and Device related complications

    Procedure complications include pneumothorax, hemothorax, and air embolism. Device related complications include lead and pocket complications

    Time frame: 6 months

  3. ΔLVEDD between baseline and six months post-discharge

    ΔLVEDD:change in LVEDD between baseline and six months after procedure between two groups

    Time frame: 6 months

  4. ΔLVEDV between baseline and six months post-discharge

    ΔLVEDV:change in LVEDV between baseline and six months after procedure between two groups

    Time frame: 6 months

  5. The echocardiographic response rate of LVEF increase ≥5%

    the percentage of patients with change of LVEF ≥5% at 6 month from baseline

    Time frame: 6 months

  6. The changes of NT-proBNP betwen baseline and 6 months post-discharge

    The changes of NT-proBNP betwen baseline and 6 months post-discharge

    Time frame: 6 months

  7. Composite incidence rate of all-cause mortality and/or hospitalization for heart failure

    All-cause death: including cardiovascular and non-cardiovascular deaths. Hospitalization for heart failure: an unplanned outpatient or emergency department visit or inpatient hospitalization in which the patient presented with signs and symptoms consistent with heart failure and required medication therapy.

    Time frame: 6 months

  8. The echocardiographic response rate of LVEF increase ≥15%

    an increase in LVESV ≥15% during follow-up at 6 month compared with baseline

    Time frame: 6 months

  9. The rate of ΔLVESV ≥15% between baseline and six months post-discharge

    the percentage of patients with change of ΔLVESV ≥15% at 6 month from baseline

    Time frame: 6 months

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2024, 29 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 29 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Sep 22, 2022
StartActual
Jul 18, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05549544
Lead sponsor
Fu Wai Hospital, Beijing, China
Responsible party
Xiaohan Fan (Professor, MD, PhD, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Sep 22, 2022
Start date
Jul 18, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 10, 2024

Study contacts

Haojie Zhu, M.D
Contact
13167310573@163.com
+8613167310573
Xiaofei Li, M.D
Contact
lixiaofei0103@163.com
+8617801013995
Xiaohan Fan, PhD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion